Prestige Biopharma Pte. Ltd.

Astellas Pharma ’s Vyloy (zolbetuximab) is on track to secure EU-wide approval for treating gastric or gastro-esophageal junction adenocarcinoma, while Ipsen ’s Iqirvo (elafibranor) is poised to rece

Amid prolonged difficulties in the financing environment this year, South Korean biotech firms including Genexine Inc. and Bridge Biotherapeutics, Inc. have opted to suspend low-priority R&D proje

Pfizer ’s interest in its biosimilars business appears to be on the decline. The firm will no longer split out quarterly results for the segment from its Q3 earnings release report onward, and made li

Prestige Biopharma says a meeting with the FDA in November represents a “final step” before filing its HD201 trastuzumab rival to Herceptin, also known as Tuznue, with the US agency by the end of the